BIOADAPTIVES, INC.
For the period ended Dec 31, 2025. Filed Apr 14, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 14, 2026
What changed in Management’s Discussion and Analysis?
Read the current filingPrevious report: 10-K
Period ended 2024-12-31; filed 2025-04-15.
0001640334-25-000660
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of OperationsCurrent report: 10-K
Period ended 2025-12-31; filed 2026-04-14.
0001640334-26-000718
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of OperationsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 44 previous paragraphs and 41 current paragraphs.
10 unchanged; 22 reworded; 9 added; 10 removed; 2 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (9)
Current report
BioAdaptives' core business is to investigate, market, and distribute natural plant, algal, and cyanobacteria-based products and medical devices that enhance health and wellness for humans and animals, with a focus on nootropics, anti-aging, weight control, relaxation, pain relief, and anti-viral benefits. BioAdaptives is reformulating its entire product line and started bringing out new products from the second quarter of 2025.
Current report
Effective November 15, 2021, the Company entered into a marketing agreement for an FDA-cleared Class Tl medical device, the Lung Flute™. In April 2024, The Company negotiated with the sole owner of the product to assume their existing stock and their rights to all future activities on this item. It intends to actively expand its sales efforts beyond the direct sales effort of its Lung Cleanser to target medical communities, pharmacies, gyms, athletic clubs, and senior communities, both in the US and internationally. The Company is also exploring agreements with other medical device manufacturers, the owners of intellectual property related to medical devices and processes, as well as marketing companies associated with these manufacturers and owners.
Current report
The Company's current products in development include dietary supplements utilizing natural ingredients and proprietary methods to optimize the availability of nutrients in foods and beverages. The human products are designed to aid in cognitive health, regenerative stem cell activation, and healthy weight loss. MyndMed™ provides Immediate cognitive enhancement (focus, clarity, motivation), medium-term resilience and memory gains, and long-term neuroprotection and cognitive health, making it a robust solution for anyone seeking to optimize mental performance and brain longevity. Zeranovia™ is a healthy weight loss enhancer, and Wynovia™ is used to help reduce the loss of lean muscle mass during dieting.
Current report
Beginning in April, the Company completed preparations to launch the Canine Product – PawPa® Regen. Backed by science and advanced technology, PawPa®’s products not only enhance pet wellness but also set the new standard in pet care. “Regen” dog chew PawPa®’s flagship product is crafted with a blend of advanced nutraceutical compounds and infused with all-natural ingredients; these chews are specially formulated to enhance canines’ quality of life in their golden years. Specific benefits of the “Regen™” chew include Regenerative Support, Energy & Vitality, and Anti-aging Benefits.
Current report
The Company’s Product MyndMed™ is completing its pre-launch phase. MyndMed™ is designed to optimize multiple neurotransmitter systems and neuroprotective pathways, delivering broad-spectrum cognitive benefits. By synergistically targeting acetylcholine, dopamine, neuroprotection, synaptic growth, and stress reduction, MyndMed™ supports both immediate and sustained improvements in mental performance, resilience, and brain health.
Current report
It aids in a rapid increase in motivation, sustained attention, and mental clarity, and helps in tackling demanding cognitive tasks with greater drive and efficiency. The product underwent rigorous testing by TruShield and received its TruShield Certified Certification, which provides the brand with a trusted, science-backed way to demonstrate that the product is free from banned substances.
Current report
Xcellara™ is BioAdaptives’ regenerative wellness solution to enhance your performance, accelerate recovery, and revitalize your health. Backed by double-blind placebo-controlled clinical trials, Xcellara™ activates stem cells for cellular regeneration. Derived from a proprietary blend of nutraceutical compounds, Xcellara™ is the secret weapon for success on and off the court, providing a myriad of benefits. In its market testing, Xcellera™ has demonstrated a positive effect on individuals challenged by chronic fatigue.
Current report
Zeranovia™ has been going through a further refining process. It is about to complete its clinical trial for launching in the last quarter. Zeranovia™ is an innovative, natural weight loss supplement designed to work exceptionally well on its own or as a complement to GLP-1 and GIP weight loss treatments such as Ozempic, Wegovy, Zepbound, and Mounjaro. It supports weight loss by dramatically suppressing appetite, enhancing insulin sensitivity, preserving muscle mass, and delivering essential nutrients. Zeranovia™ significantly improves the effectiveness of existing treatments while providing substantial nutritional support to prevent muscle wasting during a caloric deficit. Throughout the trial, extremely encouraging results have been reported of participants losing 5 to 11 pounds in a 7 to 10 day period.
Current report
The Company has minimal revenues for years ended December 31, 2025, and December 31, 2024, of 18,278 and $ 12,669 respectively.
Removed paragraphs (10)
Previous report
Item 7 - Management’s Discussion and Analysis of Financial Condition and Results of Operations
Previous report
(1) Caution Regarding Forward-Looking Information
Previous report
BioAdaptives’ core business is investigating, marketing, and distributing natural plant, fungi, and algal-based products and medical devices that improve health and wellness for humans and animals. The company emphasizes weight control, pain relief, antiviral function, and anti-aging properties.
Previous report
The Company’s current products in development include a weight management supplement in a Human Clinical Trial, Zeranovia™. Zeranovia™ is made of natural ingredients and uses proprietary methods of optimizing the availability of nutrients in foods and beverages. The trials are proceeding positively, with consistent weight loss with minimal side effects. Zeranovia™ empowers users to lose weight while maintaining more lean muscle mass. Based on current results, Zeranovia™ is expected to be introduced commercially in the second quarter of 2025.
Previous report
Xcellara™ regenerative stem cell activator is in production and is expected to be sold commercially in April 2025. PawPa™ Regen, the canine treat stem cell activator, will be available for delivery in early April 2025 with the first finished product delivered to the warehouse on March 28, 2025. PawPa™ Regen supports anti-aging, wellness, and overall responsiveness. These formulations are based upon extensive trials on humans, dogs, horses, hogs, and mice. The canine products are all in the form of treats, making delivery and dosing very simple and effective.
Previous report
At the request of a member of the BioAdaptives Board of Advisors, BioAdaptives developed an advanced nootropic, MyndMed™, it focuses on diverse pathways, delivering acetylcholine (focus), dopamine (mood), GABA (calm), antioxidants (protection), and energy (increased mitochondria) while avoiding tolerance and extending impact. MyndMed™ is designed to improve memory, learning, cognitive enhancement, mood support, neuroprotection, neuroplasticity, and stress resilience. It’s designed for a fast increase of focus and clarity today and long-term benefits for memory and brain health for weeks and months. It works with your biology to improve your mind.
Previous report
We continue researching and developing new nutraceutical products for humans and animals to solve problems and deliver the best-in-class products. Our products are unique, well-designed, and proven to bring benefits, not just copies of other products.
Previous report
The Company has minimal revenues for the years ending December 31, 2024, and December 31, 2023, of $12,669 and $28,565, respectively. On May 21, 2024, Mr. James Keener was elected to be the CEO of BioAdaptives on May 15, 2024. After thoroughly analyzing BioAdaptives’ product line, Keener canceled all dietary supplement products. Keener had been working with his team for over one year on developing meaningful dietary supplements. This resulted in no revenue from May 15, 2024, to the present.
Previous report
One of the primary products Keener brought to the table was the Weight Management product Zeranovia™. Based on strong relationships with others, Keener was able to obtain an Institutional Review Board (IRB) approval for the product. It is now in Human Clinical Trials, and results show it is ready for market. A strong competitor to GLP-1 and GIP agonists, it has been shown to increase Cholecystokinin (CCK) an important weight loss peptide. Zeranovia™ is expected to be a successful product in 2025, with the first revenue for the new product line coming in during the second quarter.
Previous report
Three new and proven products will enter the retail market in the second quarter: Xcellara™ (being bottled in Las Vegas now), PawPa™ Regen (the Finished product was recently delivered to our warehouse), MyndMed™ (currently in production), and Zeranovia™. It is expected that they will be manufactured in 12 weeks.
Reworded paragraphs (22)
Previous wording
Certain statements contained in this annual filing, including, without limitation, statements containing the words “believes”, “anticipates”, “expects” and words of similar import, constitute forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
Current wording
(1) Caution Regarding Forward-Looking Information Certain statements contained in this annual filing, including, without limitation, statements containing the words "believes", "anticipates", "expects" and words of similar import, constitute forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
Previous wording
Such factors include, among others, the following: international, national and local general economic and market conditions: demographic changes; the ability of the Company to sustain, manage or forecast its growth; the ability of the Company to successfully make and integrate acquisitions; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; and other factors referenced in this and previous filings.
Current wording
Such factors include, among others, the following: international, national and local general economic and market conditions: demographic changes; the ability of the Company to sustain, manage or forecast its growth; the ability of the Company to successfully make and integrate acquisitions; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; and other factors referenced in this and previous filings.Given these uncertainties, readers of this Form 10-K and investors are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.
Previous wording
On March 31, 2017, the Company filed Form 15-15D with the SEC, terminating its status as an SEC-reporting company; it was current in its Continuous Disclosure obligations at that time. The Company continued to provide financial and other reports to shareholders and the public by means of the Alternative Reporting System operated by OTC Markets Group, Inc. Its shares continued to trade in the OTCMarkets, and it also continued to execute its business plan.
Current wording
On March 31, 2017, the Company filed a Form 15-15D with the SEC, terminating its status as an SEC-reporting company; it was current in its Continuous Disclosure obligations at that time. The Company continued to provide financial and other reports to shareholders and the public by means of the Alternative Reporting System operated by OTC Markets Group, Inc. Its shares continued to trade in the OTC market and it also continued to execute its business plan.
Previous wording
On May 10, 2019, the Company filed Form 10-12g with the SEC, re-entering the Continuous Disclosure program and registering its common stock under Section 12(g) of the Securities Exchange Act of 1934. On August 1, 2019, the SEC staff informed the Company that it had no further comments on this filing.
Current wording
On May 10, 2019, the Company filed a Form 10-12g with the SEC, re-entering the Continuous Disclosure program and registering its common stock under Section 12(g) of the Securities Exchange Act of 1934. On August 1, 2019, the SEC staff informed the Company that it had no further comments on this filing.
Previous wording
On September 11, 2019, the Company appointed Robert Ellis as President and Ron Lambrecht as Chief Financial Officer. Dr. Jacobs remained Chief Executive Officer.
Current wording
On September 11, 2019, the Company appointed Robert Ellis as President and Ron Lambrecht as Chief Financial Officer. Dr. Jacobs remained as Chief Executive Officer.
Previous wording
On February 6, 2020, the Board of Directors exercised its authority under the Delaware General Corporations Law to establish its Series A Preferred Stock. Series A has enhanced voting and conversion privileges and can be used by the Company to settle recorded debt or exchange for new product rights or techniques. On this same day, the Board of Directors authorized an increase in the Company’s authorized common stock from 100,000,000 to 200,000,000; holders of a majority of the Company’s common shares consented to the increase.
Current wording
On February 6, 2020, the Board of Directors exercised its authority under the Delaware General Corporations Law to establish its Series A Preferred Stock. The Series A has enhanced voting and conversion privileges and can be used by the Company to settle recorded debt or exchange for new product rights or techniques. On this same day, the Board of Directors authorized an increase in the Company’s authorized common stock from 100,000,000 to 200,000,000; holders of a majority of the Company’s common shares consented to the increase.
Previous wording
On January 26, 2022, the Board of Directors exercised its authority under the Delaware General Corporations Law to establish its Series B Preferred Stock. Series B has enhanced voting and conversion privileges and can be used by the Company to acquire ownership of intellectual property rights and other assets. On this same day, the Board of Directors authorized an increase in the Company’s authorized common stock from 200,000,000 to 750,000,000; this increase received the consent of the holders of a majority of the Company’s common shares.
Current wording
On January 26, 2022, the Board of Directors exercised its authority under the Delaware General Corporations Law to establish its Series B Preferred Stock. The Series B has enhanced voting and conversion privileges and can be used by the Company to acquire ownership of intellectual property rights and other assets. On this same day, the Board of Directors authorized an increase in the Company’s authorized common stock from 200,000,000 to 750,000,000; this increase received the consent of the holders of a majority of the Company’s common shares. consented to the increase
Previous wording
On March 18, 2022, the Company filed Form 1-A with the Securities and Exchange Commission covering a plan to sell up to 200,000,000 shares of common stock for prices between .005 and .01 per share. This was amended on October 7 2022 to 250,000,000 shares of common stock at the price of 0.001.
Current wording
On March 18, 2022, the Company filed a Form 1-A with the Securities and Exchange Commission covering a plan to sell up to 200,000,000 shares of common stock for prices between .005 and .01 per share. This was amended on October 7 2022 to 250,000,000 shares of common stock at the price of 0.001.
Previous wording
On May 15, 2024, Dr. Edward Jacobs retired from the Company and was succeeded by Mr. James E. Kneer as Chairman and CEO. As of May 27, 2024, Mr. Gimhana Dissanayake joined him as a Director of the Company.
Current wording
On May 15 2024, Dr. Edward Jacobs retired from the Company and was succeeded by Mr James E Kneer as Chairman and CEO. Mr. Gimhana Dissanayake joined him as a Director of the Company as of May 27, 2024.
Previous wording
On December 3, 2024, the Board approved a One-for-One Stock Dividend to holders of common stock.
Current wording
On October 28, 2024, the Board unanimously resolved move forward with a reverse split of 1 for 300 shares. On December 3, 2024 the Board of Directors Approved a One-for-One Stock Dividend to holders of common stock.
Previous wording
In conjunction with the Company’s business plan, as discussed in Item I of this document, the Company has expended considerable effort and financial resources to implement its business plan. The Company incurred operating expenses of $429,026, which required cash payments of $254,119, which was principally funded through convertible debt as disclosed in the accompanying financial statement footnotes and advances from shareholders. The operating expenses were for activities that did not require cash payments, including stock-based compensation and a discount for the amortization of debt.
Current wording
In conjunction with the Company’s business plan, as discussed in Item I of this document, the Company has expended considerable effort and financial resources to the implementation of its business plan. The Company incurred operating expenses of $1,054688 which required cash payments of $516,254, which was principally funded through shareholder investments and loans as disclosed in the accompanying financial statement footnotes. The balance of the operating expenses was for activities that did not require cash payments, including stock-based compensation and a discount for amortization of debt.
Previous wording
Earnings (Loss) per share for the respective years ended December 31, 2023, and December 31, 2024, were $0.11 and $0.12, respectively, based on the weighted-average shares issued and outstanding at the end of each respective period.
Current wording
Earnings (Loss) per share for the respective years ended December 31,2023 and December 31, 2024, were $( 0.15 ) and ( 0.11 ), respectively, based on the weighted-average shares issued and outstanding at the end of each respective period.
Previous wording
We anticipate that future expenditure levels will remain relatively consistent until the Company fully implements its current business plan, at which time the Company’s expenses and working capital requirements may increase significantly. The Company does not expect to generate any meaningful revenue or incur operating expenses for purposes other than fulfilling the obligations of a reporting company under the Exchange Act unless and until such time that the Company begins meaningful operations.
Current wording
We anticipate that future expenditure levels will remain relatively consistent until such time that the Company fully implements its current business plan, at which time the Company’s expenses and working capital requirements may increase significantly. The Company does not expect to generate any meaningful revenue or incur operating expenses for purposes other than fulfilling the obligations of a reporting company under the Exchange Act unless and until such time that the Company begins meaningful operations.
Previous wording
Subject to financing and various regulatory approvals, the Company intends to 1) market its existing products as described herein; 2) continue conducting research and investigation activities to identify new products or markets and improve its existing products and marketing; and 3) seek strategic or complimentary acquisitions in its current market space or, if indicated, others. There is no guarantee that the Company will be able to implement this business plan successfully or that if implemented, said plan will be successful.
Current wording
Subject to financing and various regulatory approvals, the Company intends to 1) market its existing products as described herein; 2) continue conducting research and investigation activities to identify new products or markets and improve its existing products and marketing; and 3) seek strategic or complimentary acquisitions in its current market space or, if indicated, others. There is no guarantee that the Company will be able to successfully implement this business plan or that if implemented, said plan will be successful.
Previous wording
On December 31, 2023 and 2024, the Company had working capital of approximately $88,557 and $261,885, including all related party accounts receivable, accrued expenses, and line-of-credit notes payable.
Current wording
On December 31, 2024 and 2025, respectively, the Company had working capital of approximately $ 225,901 and $261,885; inclusive of all related party accounts receivable, accrued expenses and line-of-credit notes payable.
Previous wording
It is the belief of management that our current finance partners, shareholders, and the proceeds from our sales of Preferred D will be able to provide sufficient working capital necessary to support and preserve the integrity of the corporate entity. However, there is no legal obligation for either management or significant stockholders to provide additional future funding, and we cannot be assured as to the success of our offering. Further, the Company is at the mercy of future economic trends and business operations. Consequently, there is substantial doubt about the Company’s ability to continue as a going concern.
Current wording
It is the belief of management that our current finance partners, shareholders and the proceeds from our sales of Preferred D will be able provide sufficient working capital necessary to support and preserve the integrity of the corporate entity. However, there is no legal obligation for either management or significant stockholders to provide additional future funding and we cannot be assured as to the success of our offering. Further, the Company is at the mercy of future economic trends and business operations. Consequently, there is substantial doubt about the Company's ability to continue as a going concern.
Previous wording
The Company’s need for working capital may change dramatically due to any future business transaction.
Current wording
The Company's need for working capital may change dramatically as a result of any future business transaction.
Previous wording
There can be no assurance that the Company will identify or enter into any business transaction in the future. Further, there can be no assurance that the Company would successfully consummate any acquisition on favorable terms or that it will profitably manage the business, product, technology, or company it acquires.
Current wording
There can be no assurance that the Company will identify or enter into any business transaction in the future. Further, there can be no assurance that the Company would be successful in consummating any acquisition on favorable terms or that it will be able to profitably manage the business, product, technology or company it acquires.
Previous wording
The Company has no current plans, proposals, arrangements, or understandings regarding the sale or issuance of additional securities prior to the location of a potential business transaction. Accordingly, there can be no assurance that sufficient funds will be available to the Company to cover the expenses related to such activities.
Current wording
The Company has no current plans, proposals, arrangements or understandings with respect to the sale or issuance of additional securities prior to the location of a potential business transaction. Accordingly, there can be no assurance that sufficient funds will be available to the Company to allow it to cover the expenses related to such activities.
Previous wording
Whether the Company’s cash assets prove inadequate to meet its operational needs, the Company might seek to compensate service providers by issuing stock in lieu of cash.
Current wording
Regardless of whether the Company’s cash assets prove to be inadequate to meet the Company’s operational needs, the Company might seek to compensate providers of services by issuances of stock in lieu of cash.
Previous wording
Our financial statements and related public financial information are based on applying accounting principles generally accepted in the United States (“GAAP”). GAAP requires using estimates, assumptions, judgments, and subjective interpretations of accounting principles that impact the assets, liabilities, revenue, and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures, including information regarding contingencies, risk, and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied. We base our estimates on historical experience and various other assumptions that we believe are reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made while preparing our financial statements.
Current wording
Our financial statements and related public financial information are based on the application of accounting principles generally accepted in the United States (“GAAP”). GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenue and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.
Previous wording
Our significant accounting policies are summarized in Note 2 of our financial statements. While all these significant accounting policies impact on our financial condition and results of operations, we view sure of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our financial statements and require management to use a greater degree of judgment and estimates. Actual results may differ from those estimates. Our management believes that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause an effect on our results of operations, financial position, or liquidity for the periods presented in this report.
Current wording
Our significant accounting policies are summarized in Note 2 of our financial statements. While all these significant accounting policies impact on our financial condition and results of operations, we view certain of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our financial statements and require management to use a greater degree of judgment and estimates. Actual results may differ from those estimates. Our management believes that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause effect on our results of operations, financial position or liquidity for the periods presented in this report.
Rearranged previous paragraphs (2)
Previous report — wording carried elsewhere
Given these uncertainties, readers of this Form 10-K and investors are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.
Previous report — wording carried elsewhere
On October 28, 2024, the Board unanimously resolved to proceed with a reverse split of 1 for 300 shares.